top of page
TELESCOPE
NEOADJUVANT PEMBROLIZUMAB AND CARBOPLATIN PLUS PACLITAXEL FOR STAGE I TRIPLE-NEGATIVE BREAST CANCER (TELESCOPE)
THE STUDY WILL EVALUATE AN ANTHRACYCLINE-FREE REGIMEN FOR PATIENTS WITH T1CN0 TRIPLE-NEGATIVE BREAST CANCER. THE PRIMARY OBJECTIVE IS TO EVALUATE THE PATHOLOGICAL COMPLETE RESPONSE RATE DEFINED AS THE PERCENTAGE OF PATIENTS WITH YPT0/IS, YPN0 AT SURGERY BASED ON LOCAL ASSESSMENT.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast Cancer
30
II
Spain
Set-up
CLINICAL TRIAL DETAILS
PRESS RELEASE
SCIENTIFIC IMPACT
ESMO 2025 poster: https://drive.google.com/file/d/1Y24C2VPt4YNfiMQCKwfcloTvTud5rGAf/view?usp=drive_link | ESMO 2025 lay language summary: https://drive.google.com/file/d/1L4FLh0ypKTKpoSphCRBXmpZF7WmLfwWL/view?usp=drive_link
BLOG ARTICLES RELATED
TRIAL SITES
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page